HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure

Immunity

Volumn 48, Issue 5, 2018, Pages 855-871

  Kwong, Peter D ^a   Mascola, John R ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CROSS REACTING ANTIBODY; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

B LYMPHOCYTE; BINDING SITE; CROSS REACTION; DRUG DESIGN; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; NONHUMAN; ONTOGENY; PRIORITY JOURNAL; REVIEW; ANIMAL; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MOUSE; PHYSIOLOGY; VIROLOGY;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; B-LYMPHOCYTES; EPITOPES; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; MICE;

EID: 85046663340     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2018.04.029     Document Type: Review

References (200)

1. Abbott, R.K., Lee, J.H., Menis, S., Skog, P., Rossi, M., Ota, T., Kulp, D.W., Bhullar, D., Kalyuzhniy, O., Havenar-Daughton, C., et al. Precursor frequency and affinity determine B cell competitive fitness in germinal centers, tested with germline-targeting HIV vaccine immunogens. Immunity 48 (2018), 133–146.e6.
2. Agrawal-Gamse, C., Luallen, R.J., Liu, B., Fu, H., Lee, F.H., Geng, Y., Doms, R.W., Yeast-elicited cross-reactive antibodies to HIV Env glycans efficiently neutralize virions expressing exclusively high-mannose N-linked glycans. J. Virol. 85 (2011), 470–480.
3. Alam, S.M., Aussedat, B., Vohra, Y., Meyerhoff, R.R., Cale, E.M., Walkowicz, W.E., Radakovich, N.A., Anasti, K., Armand, L., Parks, R., et al. Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. Sci. Transl. Med., 9, 2017, 9.
4. Andrabi, R., Voss, J.E., Liang, C.H., Briney, B., McCoy, L.E., Wu, C.Y., Wong, C.H., Poignard, P., Burton, D.R., Identification of common features in prototype broadly neutralizing antibodies to HIV envelope V2 apex to facilitate vaccine design. Immunity 43 (2015), 959–973.
5. Azoitei, M.L., Correia, B.E., Ban, Y.E., Carrico, C., Kalyuzhniy, O., Chen, L., Schroeter, A., Huang, P.S., McLellan, J.S., Kwong, P.D., et al. Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold. Science 334 (2011), 373–376.
6. Barnes, C.O., Gristick, H.B., Freund, N.T., Escolano, A., Lyubimov, A.Y., Hartweger, H., West, A.P. Jr., Cohen, A.E., Nussenzweig, M.C., Bjorkman, P.J., Structural characterization of a highly-potent V3-glycan broadly neutralizing antibody bound to natively-glycosylated HIV-1 envelope. Nat. Commun., 9, 2018, 1251.
7. Barouch, D.H., Whitney, J.B., Moldt, B., Klein, F., Oliveira, T.Y., Liu, J., Stephenson, K.E., Chang, H.W., Shekhar, K., Gupta, S., et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503 (2013), 224–228.
8. Bhiman, J.N., Anthony, C., Doria-Rose, N.A., Karimanzira, O., Schramm, C.A., Khoza, T., Kitchin, D., Botha, G., Gorman, J., Garrett, N.J., et al. Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. Nat. Med. 21 (2015), 1332–1336.
9. Bird, G.H., Irimia, A., Ofek, G., Kwong, P.D., Wilson, I.A., Walensky, L.D., Stapled HIV-1 peptides recapitulate antigenic structures and engage broadly neutralizing antibodies. Nat. Struct. Mol. Biol. 21 (2014), 1058–1067.
10. Bonsignori, M., Hwang, K.K., Chen, X., Tsao, C.Y., Morris, L., Gray, E., Marshall, D.J., Crump, J.A., Kapiga, S.H., Sam, N.E., et al. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J. Virol. 85 (2011), 9998–10009.
11. Bonsignori, M., Montefiori, D.C., Wu, X., Chen, X., Hwang, K.K., Tsao, C.Y., Kozink, D.M., Parks, R.J., Tomaras, G.D., Crump, J.A., et al. Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. J. Virol. 86 (2012), 4688–4692.
12. Bonsignori, M., Zhou, T., Sheng, Z., Chen, L., Gao, F., Joyce, M.G., Ozorowski, G., Chuang, G.Y., Schramm, C.A., Wiehe, K., et al., NISC Comparative Sequencing Program. Maturation pathway from germline to broad HIV-1 neutralizer of a CD4-mimic antibody. Cell 165 (2016), 449–463.
13. Bonsignori, M., Liao, H.X., Gao, F., Williams, W.B., Alam, S.M., Montefiori, D.C., Haynes, B.F., Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development. Immunol. Rev. 275 (2017), 145–160.
14. Boyington, J.C., Joyce, M.G., Sastry, M., Stewart-Jones, G.B., Chen, M., Kong, W.P., Ngwuta, J.O., Thomas, P.V., Tsybovsky, Y., Yang, Y., et al. Structure-based design of head-only fusion glycoprotein immunogens for respiratory syncytial virus. PLoS ONE, 11, 2016, e0159709.
15. Briney, B.S., Willis, J.R., Crowe, J.E. Jr., Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes. PLoS ONE, 7, 2012, e36750.
16. Briney, B.S., Willis, J.R., Hicar, M.D., Thomas, J.W. 2nd, Crowe, J.E. Jr., Frequency and genetic characterization of V(DD)J recombinants in the human peripheral blood antibody repertoire. Immunology 137 (2012), 56–64.
17. Briney, B., Sok, D., Jardine, J.G., Kulp, D.W., Skog, P., Menis, S., Jacak, R., Kalyuzhniy, O., de Val, N., Sesterhenn, F., et al. Tailored immunogens direct affinity maturation toward HIV neutralizing antibodies. Cell 166 (2016), 1459–1470.e11.
18. Burton, D.R., Antibodies, viruses and vaccines. Nat. Rev. Immunol. 2 (2002), 706–713.
19. Burton, D.R., Hangartner, L., Broadly neutralizing antibodies to HIV and their role in vaccine design. Annu. Rev. Immunol. 34 (2016), 635–659.
20. Burton, D.R., Mascola, J.R., Antibody responses to envelope glycoproteins in HIV-1 infection. Nat. Immunol. 16 (2015), 571–576.
21. Burton, D.R., Pyati, J., Koduri, R., Sharp, S.J., Thornton, G.B., Parren, P.W., Sawyer, L.S., Hendry, R.M., Dunlop, N., Nara, P.L., et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266 (1994), 1024–1027.
22. Burton, D.R., Desrosiers, R.C., Doms, R.W., Koff, W.C., Kwong, P.D., Moore, J.P., Nabel, G.J., Sodroski, J., Wilson, I.A., Wyatt, R.T., HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5 (2004), 233–236.
23. Burton, D.R., Stanfield, R.L., Wilson, I.A., Antibody vs. HIV in a clash of evolutionary titans. Proc. Natl. Acad. Sci. USA 102 (2005), 14943–14948.
24. Calarese, D.A., Scanlan, C.N., Zwick, M.B., Deechongkit, S., Mimura, Y., Kunert, R., Zhu, P., Wormald, M.R., Stanfield, R.L., Roux, K.H., et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300 (2003), 2065–2071.
25. Cale, E.M., Gorman, J., Radakovich, N.A., Crooks, E.T., Osawa, K., Tong, T., Li, J., Nagarajan, R., Ozorowski, G., Ambrozak, D.R., et al. Virus-like particles identify an HIV V1V2 apex-binding neutralizing antibody that lacks a protruding loop. Immunity 46 (2017), 777–791.e10.
26. Cardoso, R.M., Zwick, M.B., Stanfield, R.L., Kunert, R., Binley, J.M., Katinger, H., Burton, D.R., Wilson, I.A., Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 22 (2005), 163–173.
27. Caskey, M., Klein, F., Lorenzi, J.C., Seaman, M.S., West, A.P. Jr., Buckley, N., Kremer, G., Nogueira, L., Braunschweig, M., Scheid, J.F., et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522 (2015), 487–491.
28. Caskey, M., Schoofs, T., Gruell, H., Settler, A., Karagounis, T., Kreider, E.F., Murrell, B., Pfeifer, N., Nogueira, L., Oliveira, T.Y., et al. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat. Med. 23 (2017), 185–191.
29. Chakrabarti, B.K., Walker, L.M., Guenaga, J.F., Ghobbeh, A., Poignard, P., Burton, D.R., Wyatt, R.T., Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity. J. Virol. 85 (2011), 8217–8226.
30. Chen, L., Kwon, Y.D., Zhou, T., Wu, X., O'Dell, S., Cavacini, L., Hessell, A.J., Pancera, M., Tang, M., Xu, L., et al. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 326 (2009), 1123–1127.
31. Chuang, G.Y., Geng, H., Pancera, M., Xu, K., Cheng, C., Acharya, P., Chambers, M., Druz, A., Tsybovsky, Y., Wanninger, T.G., et al. Structure-based design of a soluble prefusion-closed HIV-1 Env trimer with reduced CD4 affinity and improved immunogenicity. J. Virol., 91, 2017, 91.
32. Chuang, G.Y., Zhou, J., Rawi, R., Shen, C.H., Sheng, Z., West, A.P., Jr., Zhang, B., Zhou, T., Bailer, R.T., Doria-Rose, N.A., et al. (2018). Structural survey of HIV-1-neutralizing antibodies targeting Env trimer delineates epitope categories and suggests vaccine templates. bioRxiv. https://doi.org/10.1101/312579.
33. Colman, P.M., Lawrence, M.C., The structural biology of type I viral membrane fusion. Nat. Rev. Mol. Cell Biol. 4 (2003), 309–319.
34. Correia, B.E., Ban, Y.E., Holmes, M.A., Xu, H., Ellingson, K., Kraft, Z., Carrico, C., Boni, E., Sather, D.N., Zenobia, C., et al. Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. Structure 18 (2010), 1116–1126.
35. Correia, B.E., Bates, J.T., Loomis, R.J., Baneyx, G., Carrico, C., Jardine, J.G., Rupert, P., Correnti, C., Kalyuzhniy, O., Vittal, V., et al. Proof of principle for epitope-focused vaccine design. Nature 507 (2014), 201–206.
36. Corti, D., Voss, J., Gamblin, S.J., Codoni, G., Macagno, A., Jarrossay, D., Vachieri, S.G., Pinna, D., Minola, A., Vanzetta, F., et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333 (2011), 850–856.
37. Crowe, J.E. Jr., Teaching a clone to walk, one step at a time. Cell 166 (2016), 1360–1361.
38. de Taeye, S.W., Ozorowski, G., Torrents de la Peña, A., Guttman, M., Julien, J.P., van den Kerkhof, T.L., Burger, J.A., Pritchard, L.K., Pugach, P., Yasmeen, A., et al. Immunogenicity of stabilized HIV-1 envelope trimers with reduced exposure of non-neutralizing epitopes. Cell 163 (2015), 1702–1715.
39. Derdeyn, C.A., Decker, J.M., Bibollet-Ruche, F., Mokili, J.L., Muldoon, M., Denham, S.A., Heil, M.L., Kasolo, F., Musonda, R., Hahn, B.H., et al. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303 (2004), 2019–2022.
40. Dey, B., Svehla, K., Xu, L., Wycuff, D., Zhou, T., Voss, G., Phogat, A., Chakrabarti, B.K., Li, Y., Shaw, G., et al. Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site. PLoS Pathog., 5, 2009, e1000445.
41. Dingens, A.S., Acharya, P., Haddox, H.K., Rawi, R., Xu, K., Chuang, G.Y., Wei, H., Mascola, J.R., Carragher, B., Potter, C.S., et al. (2018). Complete functional mapping of infection- and vaccine-elicited antibodies against the fusion peptide of HIV. bioRxiv. https://doi.org/10.1101/307587.
42. Doria-Rose, N.A., Klein, R.M., Daniels, M.G., O'Dell, S., Nason, M., Lapedes, A., Bhattacharya, T., Migueles, S.A., Wyatt, R.T., Korber, B.T., et al. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J. Virol. 84 (2010), 1631–1636.
43. Doria-Rose, N.A., Schramm, C.A., Gorman, J., Moore, P.L., Bhiman, J.N., DeKosky, B.J., Ernandes, M.J., Georgiev, I.S., Kim, H.J., Pancera, M., et al., NISC Comparative Sequencing Program. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 509 (2014), 55–62.
44. Doria-Rose, N.A., Bhiman, J.N., Roark, R.S., Schramm, C.A., Gorman, J., Chuang, G.Y., Pancera, M., Cale, E.M., Ernandes, M.J., Louder, M.K., et al. New member of the V1V2-directed CAP256-VRC26 lineage that shows increased breadth and exceptional potency. J. Virol. 90 (2015), 76–91.
45. Dosenovic, P., von Boehmer, L., Escolano, A., Jardine, J., Freund, N.T., Gitlin, A.D., McGuire, A.T., Kulp, D.W., Oliveira, T., Scharf, L., et al. Immunization for HIV-1 broadly neutralizing antibodies in human Ig knockin mice. Cell 161 (2015), 1505–1515.
46. Doyle-Cooper, C., Hudson, K.E., Cooper, A.B., Ota, T., Skog, P., Dawson, P.E., Zwick, M.B., Schief, W.R., Burton, D.R., Nemazee, D., Immune tolerance negatively regulates B cells in knock-in mice expressing broadly neutralizing HIV antibody 4E10. J. Immunol. 191 (2013), 3186–3191.
47. Ekiert, D.C., Bhabha, G., Elsliger, M.A., Friesen, R.H., Jongeneelen, M., Throsby, M., Goudsmit, J., Wilson, I.A., Antibody recognition of a highly conserved influenza virus epitope. Science 324 (2009), 246–251.
48. Ekiert, D.C., Friesen, R.H., Bhabha, G., Kwaks, T., Jongeneelen, M., Yu, W., Ophorst, C., Cox, F., Korse, H.J., Brandenburg, B., et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333 (2011), 843–850.
49. Escolano, A., Steichen, J.M., Dosenovic, P., Kulp, D.W., Golijanin, J., Sok, D., Freund, N.T., Gitlin, A.D., Oliveira, T., Araki, T., et al. Sequential immunization elicits broadly neutralizing anti-HIV-1 antibodies in Ig knockin mice. Cell 166 (2016), 1445–1458.e12.
50. Escolano, A., Dosenovic, P., Nussenzweig, M.C., Progress toward active or passive HIV-1 vaccination. J. Exp. Med. 214 (2017), 3–16.
51. Farzan, M., Choe, H., Desjardins, E., Sun, Y., Kuhn, J., Cao, J., Archambault, D., Kolchinsky, P., Koch, M., Wyatt, R., Sodroski, J., Stabilization of human immunodeficiency virus type 1 envelope glycoprotein trimers by disulfide bonds introduced into the gp41 glycoprotein ectodomain. J. Virol. 72 (1998), 7620–7625.
52. Freund, N.T., Wang, H., Scharf, L., Nogueira, L., Horwitz, J.A., Bar-On, Y., Golijanin, J., Sievers, S.A., Sok, D., Cai, H., et al. Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller. Sci. Transl. Med., 9, 2017, 9.
53. Gao, F., Bonsignori, M., Liao, H.X., Kumar, A., Xia, S.M., Lu, X., Cai, F., Hwang, K.K., Song, H., Zhou, T., et al. Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies. Cell 158 (2014), 481–491.
54. Garces, F., Sok, D., Kong, L., McBride, R., Kim, H.J., Saye-Francisco, K.F., Julien, J.P., Hua, Y., Cupo, A., Moore, J.P., et al. Structural evolution of glycan recognition by a family of potent HIV antibodies. Cell 159 (2014), 69–79.
55. Garces, F., Lee, J.H., de Val, N., de la Pena, A.T., Kong, L., Puchades, C., Hua, Y., Stanfield, R.L., Burton, D.R., Moore, J.P., et al. Affinity maturation of a potent family of HIV antibodies is primarily focused on accommodating or avoiding glycans. Immunity 43 (2015), 1053–1063.
56. Georgiev, I.S., Doria-Rose, N.A., Zhou, T., Kwon, Y.D., Staupe, R.P., Moquin, S., Chuang, G.Y., Louder, M.K., Schmidt, S.D., Altae-Tran, H.R., et al. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Science 340 (2013), 751–756.
57. Georgiev, I.S., Joyce, M.G., Yang, Y., Sastry, M., Zhang, B., Baxa, U., Chen, R.E., Druz, A., Lees, C.R., Narpala, S., et al. Single-chain soluble BG505.SOSIP gp140 trimers as structural and antigenic mimics of mature closed HIV-1 Env. J. Virol. 89 (2015), 5318–5329.
58. Georgiev, I.S., Joyce, M.G., Chen, R.E., Leung, K., McKee, K., Druz, A., Van Galen, J.G., Kanekiyo, M., Tsybovsky, Y., Yang, E.S., et al. Two-component ferritin nanoparticles for multimerization of diverse trimeric antigens. ACS Infect Dis., 2018, 10.1021/acsinfecdis.7b00192 Published online March 6, 2018.
59. Gilbert, P.B., Juraska, M., deCamp, A.C., Karuna, S., Edupuganti, S., Mgodi, N., Donnell, D.J., Bentley, C., Sista, N., Andrew, P., et al. Basis and statistical design of the passive HIV-1 antibody mediated prevention (AMP) test-of-concept efficacy trials. Stat. Commun. Infect. Dis., 9, 2017 20160001.
60. Gorman, J., Soto, C., Yang, M.M., Davenport, T.M., Guttman, M., Bailer, R.T., Chambers, M., Chuang, G.Y., DeKosky, B.J., Doria-Rose, N.A., et al., NISC Comparative Sequencing Program. Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. Nat. Struct. Mol. Biol. 23 (2016), 81–90.
61. Gray, E.S., Madiga, M.C., Hermanus, T., Moore, P.L., Wibmer, C.K., Tumba, N.L., Werner, L., Mlisana, K., Sibeko, S., Williamson, C., et al., CAPRISA002 Study Team. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J. Virol. 85 (2011), 4828–4840.
62. Gristick, H.B., von Boehmer, L., West, A.P. Jr., Schamber, M., Gazumyan, A., Golijanin, J., Seaman, M.S., Fätkenheuer, G., Klein, F., Nussenzweig, M.C., Bjorkman, P.J., Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site. Nat. Struct. Mol. Biol. 23 (2016), 906–915.
63. Guenaga, J., Garces, F., de Val, N., Stanfield, R.L., Dubrovskaya, V., Higgins, B., Carrette, B., Ward, A.B., Wilson, I.A., Wyatt, R.T., Glycine substitution at helix-to-coil transitions facilitates the structural determination of a stabilized subtype C HIV envelope glycoprotein. Immunity 46 (2017), 792–803.e3.
64. Halper-Stromberg, A., Nussenzweig, M.C., Towards HIV-1 remission: potential roles for broadly neutralizing antibodies. J. Clin. Invest. 126 (2016), 415–423.
65. Haynes, B.F., Fleming, J., St Clair, E.W., Katinger, H., Stiegler, G., Kunert, R., Robinson, J., Scearce, R.M., Plonk, K., Staats, H.F., et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308 (2005), 1906–1908.
66. Haynes, B.F., Moody, M.A., Verkoczy, L., Kelsoe, G., Alam, S.M., Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Hum. Antibodies 14 (2005), 59–67.
67. Haynes, B.F., Kelsoe, G., Harrison, S.C., Kepler, T.B., B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat. Biotechnol. 30 (2012), 423–433.
68. Hessell, A.J., Jaworski, J.P., Epson, E., Matsuda, K., Pandey, S., Kahl, C., Reed, J., Sutton, W.F., Hammond, K.B., Cheever, T.A., et al. Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques. Nat. Med. 22 (2016), 362–368.
69. Hoot, S., McGuire, A.T., Cohen, K.W., Strong, R.K., Hangartner, L., Klein, F., Diskin, R., Scheid, J.F., Sather, D.N., Burton, D.R., Stamatatos, L., Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog., 9, 2013, e1003106.
70. Hraber, P., Seaman, M.S., Bailer, R.T., Mascola, J.R., Montefiori, D.C., Korber, B.T., Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS 28 (2014), 163–169.
71. Huang, J., Ofek, G., Laub, L., Louder, M.K., Doria-Rose, N.A., Longo, N.S., Imamichi, H., Bailer, R.T., Chakrabarti, B., Sharma, S.K., et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491 (2012), 406–412.
72. Huang, J., Kang, B.H., Pancera, M., Lee, J.H., Tong, T., Feng, Y., Imamichi, H., Georgiev, I.S., Chuang, G.Y., Druz, A., et al. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature 515 (2014), 138–142.
73. Huang, J., Kang, B.H., Ishida, E., Zhou, T., Griesman, T., Sheng, Z., Wu, F., Doria-Rose, N.A., Zhang, B., McKee, K., et al. Identification of a CD4-binding-site antibody to HIV that evolved near-pan neutralization breadth. Immunity 45 (2016), 1108–1121.
74. Ingale, J., Tran, K., Kong, L., Dey, B., McKee, K., Schief, W., Kwong, P.D., Mascola, J.R., Wyatt, R.T., Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies. J. Virol. 88 (2014), 14002–14016.
75. Irimia, A., Sarkar, A., Stanfield, R.L., Wilson, I.A., Crystallographic identification of lipid as an integral component of the epitope of HIV broadly neutralizing antibody 4E10. Immunity 44 (2016), 21–31.
76. Irimia, A., Serra, A.M., Sarkar, A., Jacak, R., Kalyuzhniy, O., Sok, D., Saye-Francisco, K.L., Schiffner, T., Tingle, R., Kubitz, M., et al. Lipid interactions and angle of approach to the HIV-1 viral membrane of broadly neutralizing antibody 10E8: Insights for vaccine and therapeutic design. PLoS Pathog., 13, 2017, e1006212.
77. Jardine, J., Julien, J.P., Menis, S., Ota, T., Kalyuzhniy, O., McGuire, A., Sok, D., Huang, P.S., MacPherson, S., Jones, M., et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 340 (2013), 711–716.
78. Jardine, J.G., Ota, T., Sok, D., Pauthner, M., Kulp, D.W., Kalyuzhniy, O., Skog, P.D., Thinnes, T.C., Bhullar, D., Briney, B., et al. HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science 349 (2015), 156–161.
79. Jardine, J.G., Kulp, D.W., Havenar-Daughton, C., Sarkar, A., Briney, B., Sok, D., Sesterhenn, F., Ereño-Orbea, J., Kalyuzhniy, O., Deresa, I., et al. HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Science 351 (2016), 1458–1463.
80. Jardine, J.G., Sok, D., Julien, J.P., Briney, B., Sarkar, A., Liang, C.H., Scherer, E.A., Henry Dunand, C.J., Adachi, Y., Diwanji, D., et al. Minimally mutated HIV-1 broadly neutralizing antibodies to guide reductionist vaccine design. PLoS Pathog., 12, 2016, e1005815.
81. Joyce, M.G., Kanekiyo, M., Xu, L., Biertümpfel, C., Boyington, J.C., Moquin, S., Shi, W., Wu, X., Yang, Y., Yang, Z.Y., et al. Outer domain of HIV-1 gp120: antigenic optimization, structural malleability, and crystal structure with antibody VRC-PG04. J. Virol. 87 (2013), 2294–2306.
82. Joyce, M.G., Wheatley, A.K., Thomas, P.V., Chuang, G.Y., Soto, C., Bailer, R.T., Druz, A., Georgiev, I.S., Gillespie, R.A., Kanekiyo, M., et al., NISC Comparative Sequencing Program. Vaccine-induced antibodies that neutralize group 1 and group 2 influenza A viruses. Cell 166 (2016), 609–623.
83. Joyce, M.G., Zhang, B., Ou, L., Chen, M., Chuang, G.Y., Druz, A., Kong, W.P., Lai, Y.T., Rundlet, E.J., Tsybovsky, Y., et al. Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV. Nat. Struct. Mol. Biol. 23 (2016), 811–820.
84. Joyce, M.G., Georgiev, I.S., Yang, Y., Druz, A., Geng, H., Chuang, G.Y., Kwon, Y.D., Pancera, M., Rawi, R., Sastry, M., et al. Soluble prefusion closed DS-SOSIP.664-Env trimers of diverse HIV-1 strains. Cell Rep. 21 (2017), 2992–3002.
85. Julien, J.P., Cupo, A., Sok, D., Stanfield, R.L., Lyumkis, D., Deller, M.C., Klasse, P.J., Burton, D.R., Sanders, R.W., Moore, J.P., et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 342 (2013), 1477–1483.
86. Julien, J.P., Sok, D., Khayat, R., Lee, J.H., Doores, K.J., Walker, L.M., Ramos, A., Diwanji, D.C., Pejchal, R., Cupo, A., et al. Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog., 9, 2013, e1003342.
87. Kallewaard, N.L., Corti, D., Collins, P.J., Neu, U., McAuliffe, J.M., Benjamin, E., Wachter-Rosati, L., Palmer-Hill, F.J., Yuan, A.Q., Walker, P.A., et al. Structure and function analysis of an antibody recognizing all influenza A subtypes. Cell 166 (2016), 596–608.
88. Kanekiyo, M., Wei, C.J., Yassine, H.M., McTamney, P.M., Boyington, J.C., Whittle, J.R., Rao, S.S., Kong, W.P., Wang, L., Nabel, G.J., Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499 (2013), 102–106.
89. Karlsson Hedestam, G.B., Fouchier, R.A., Phogat, S., Burton, D.R., Sodroski, J., Wyatt, R.T., The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat. Rev. Microbiol. 6 (2008), 143–155.
90. Keele, B.F., Giorgi, E.E., Salazar-Gonzalez, J.F., Decker, J.M., Pham, K.T., Salazar, M.G., Sun, C., Grayson, T., Wang, S., Li, H., et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. USA 105 (2008), 7552–7557.
91. Kisalu, N.K., Idris, A.H., Weidle, C., Flores-Garcia, Y., Flynn, B.J., Sack, B.K., Murphy, S., Schön, A., Freire, E., Francica, J.R., et al. A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nat. Med. 24 (2018), 408–416.
92. Kong, L., Lee, J.H., Doores, K.J., Murin, C.D., Julien, J.P., McBride, R., Liu, Y., Marozsan, A., Cupo, A., Klasse, P.J., et al. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat. Struct. Mol. Biol. 20 (2013), 796–803.
93. Kong, R., Xu, K., Zhou, T., Acharya, P., Lemmin, T., Liu, K., Ozorowski, G., Soto, C., Taft, J.D., Bailer, R.T., et al. Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. Science 352 (2016), 828–833.
94. Korber, B., Muldoon, M., Theiler, J., Gao, F., Gupta, R., Lapedes, A., Hahn, B.H., Wolinsky, S., Bhattacharya, T., Timing the ancestor of the HIV-1 pandemic strains. Science 288 (2000), 1789–1796.
95. Korber, B., Gaschen, B., Yusim, K., Thakallapally, R., Kesmir, C., Detours, V., Evolutionary and immunological implications of contemporary HIV-1 variation. Br. Med. Bull. 58 (2001), 19–42.
96. Kwon, Y.D., Pancera, M., Acharya, P., Georgiev, I.S., Crooks, E.T., Gorman, J., Joyce, M.G., Guttman, M., Ma, X., Narpala, S., et al. Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. Nat. Struct. Mol. Biol. 22 (2015), 522–531.
97. Kwon, Y.D., Chuang, G.Y., Zhang, B., Bailer, R.T., Doria-Rose, N.A., Gindin, T.S., Lin, B., Louder, M.K., McKee, K., O'Dell, S., et al. Surface-matrix screening identifies semi-specific interactions that improve potency of a near pan-reactive HIV-1-neutralizing antibody. Cell Rep. 22 (2018), 1798–1809.
98. Kwong, P.D., Mascola, J.R., Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 37 (2012), 412–425.
99. Kwong, P.D., Doyle, M.L., Casper, D.J., Cicala, C., Leavitt, S.A., Majeed, S., Steenbeke, T.D., Venturi, M., Chaiken, I., Fung, M., et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420 (2002), 678–682.
100. Kwong, P.D., Chuang, G.Y., DeKosky, B.J., Gindin, T., Georgiev, I.S., Lemmin, T., Schramm, C.A., Sheng, Z., Soto, C., Yang, A.S., et al. Antibodyomics: bioinformatics technologies for understanding B-cell immunity to HIV-1. Immunol. Rev. 275 (2017), 108–128.
101. Labrijn, A.F., Poignard, P., Raja, A., Zwick, M.B., Delgado, K., Franti, M., Binley, J., Vivona, V., Grundner, C., Huang, C.C., et al. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J. Virol. 77 (2003), 10557–10565.
102. Landais, E., Huang, X., Havenar-Daughton, C., Murrell, B., Price, M.A., Wickramasinghe, L., Ramos, A., Bian, C.B., Simek, M., Allen, S., et al. Broadly neutralizing antibody responses in a large longitudinal sub-Saharan HIV primary infection cohort. PLoS Pathog., 12, 2016, e1005369.
103. Landais, E., Murrell, B., Briney, B., Murrell, S., Rantalainen, K., Berndsen, Z.T., Ramos, A., Wickramasinghe, L., Smith, M.L., Eren, K., et al. IAVI Protocol C Investigators, IAVI African HIV Research Network. HIV envelope glycoform heterogeneity and localized diversity govern the initiation and maturation of a V2 apex broadly neutralizing antibody lineage. Immunity 47 (2017), 990–1003.e9.
104. Lee, J.H., Ozorowski, G., Ward, A.B., Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer. Science 351 (2016), 1043–1048.
105. Lee, J.H., Andrabi, R., Su, C.Y., Yasmeen, A., Julien, J.P., Kong, L., Wu, N.C., McBride, R., Sok, D., Pauthner, M., et al. A broadly neutralizing antibody targets the dynamic HIV envelope trimer apex via a long, rigidified, and anionic β-hairpin structure. Immunity 46 (2017), 690–702.
106. Liao, H.X., Lynch, R., Zhou, T., Gao, F., Alam, S.M., Boyd, S.D., Fire, A.Z., Roskin, K.M., Schramm, C.A., Zhang, Z., et al., NISC Comparative Sequencing Program. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496 (2013), 469–476.
107. Lingwood, D., McTamney, P.M., Yassine, H.M., Whittle, J.R., Guo, X., Boyington, J.C., Wei, C.J., Nabel, G.J., Structural and genetic basis for development of broadly neutralizing influenza antibodies. Nature 489 (2012), 566–570.
108. Liu, J., Ghneim, K., Sok, D., Bosche, W.J., Li, Y., Chipriano, E., Berkemeier, B., Oswald, K., Borducchi, E., Cabral, C., et al. Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus. Science 353 (2016), 1045–1049.
109. Liu, Q., Acharya, P., Dolan, M.A., Zhang, P., Guzzo, C., Lu, J., Kwon, A., Gururani, D., Miao, H., Bylund, T., et al. Quaternary contact in the initial interaction of CD4 with the HIV-1 envelope trimer. Nat. Struct. Mol. Biol. 24 (2017), 370–378.
110. Luallen, R.J., Lin, J., Fu, H., Cai, K.K., Agrawal, C., Mboudjeka, I., Lee, F.H., Montefiori, D., Smith, D.F., Doms, R.W., Geng, Y., An engineered Saccharomyces cerevisiae strain binds the broadly neutralizing human immunodeficiency virus type 1 antibody 2G12 and elicits mannose-specific gp120-binding antibodies. J. Virol. 82 (2008), 6447–6457.
111. Lynch, R.M., Boritz, E., Coates, E.E., DeZure, A., Madden, P., Costner, P., Enama, M.E., Plummer, S., Holman, L., Hendel, C.S., et al., VRC 601 Study Team. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci. Transl. Med., 7, 2015, 319ra206.
112. Lyumkis, D., Julien, J.P., de Val, N., Cupo, A., Potter, C.S., Klasse, P.J., Burton, D.R., Sanders, R.W., Moore, J.P., Carragher, B., et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 342 (2013), 1484–1490.
113. MacLeod, D.T., Choi, N.M., Briney, B., Garces, F., Ver, L.S., Landais, E., Murrell, B., Wrin, T., Kilembe, W., Liang, C.H., et al., IAVI Protocol C Investigators & The IAVI African HIV Research Network. Early antibody lineage diversification and independent limb maturation lead to broad HIV-1 neutralization targeting the Env high-mannose patch. Immunity 44 (2016), 1215–1226.
114. Mascola, J.R., Haynes, B.F., HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol. Rev. 254 (2013), 225–244.
115. Mascola, J.R., Montefiori, D.C., The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 28 (2010), 413–444.
116. Mayer, K.H., Seaton, K.E., Huang, Y., Grunenberg, N., Isaacs, A., Allen, M., Ledgerwood, J.E., Frank, I., Sobieszczyk, M.E., Baden, L.R., et al. HVTN 104 Protocol Team, and the NIAID HIV Vaccine Trials Network. Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. PLoS Med., 14, 2017, e1002435.
117. McGuire, A.T., Hoot, S., Dreyer, A.M., Lippy, A., Stuart, A., Cohen, K.W., Jardine, J., Menis, S., Scheid, J.F., West, A.P., et al. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J. Exp. Med. 210 (2013), 655–663.
118. McGuire, A.T., Gray, M.D., Dosenovic, P., Gitlin, A.D., Freund, N.T., Petersen, J., Correnti, C., Johnsen, W., Kegel, R., Stuart, A.B., et al. Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice. Nat. Commun., 7, 2016, 10618.
119. McLellan, J.S., Correia, B.E., Chen, M., Yang, Y., Graham, B.S., Schief, W.R., Kwong, P.D., Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus. J. Mol. Biol. 409 (2011), 853–866.
120. McLellan, J.S., Pancera, M., Carrico, C., Gorman, J., Julien, J.P., Khayat, R., Louder, R., Pejchal, R., Sastry, M., Dai, K., et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480 (2011), 336–343.
121. McLellan, J.S., Chen, M., Joyce, M.G., Sastry, M., Stewart-Jones, G.B., Yang, Y., Zhang, B., Chen, L., Srivatsan, S., Zheng, A., et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342 (2013), 592–598.
122. McLellan, J.S., Chen, M., Leung, S., Graepel, K.W., Du, X., Yang, Y., Zhou, T., Baxa, U., Yasuda, E., Beaumont, T., et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340 (2013), 1113–1117.
123. Medina-Ramírez, M., Garces, F., Escolano, A., Skog, P., de Taeye, S.W., Del Moral-Sanchez, I., McGuire, A.T., Yasmeen, A., Behrens, A.J., Ozorowski, G., et al. Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. J. Exp. Med. 214 (2017), 2573–2590.
124. Moore, P.L., Gorman, J., Doria-Rose, N.A., Morris, L., Ontogeny-based immunogens for the induction of V2-directed HIV broadly neutralizing antibodies. Immunol. Rev. 275 (2017), 217–229.
125. Mouquet, H., Scharf, L., Euler, Z., Liu, Y., Eden, C., Scheid, J.F., Halper-Stromberg, A., Gnanapragasam, P.N., Spencer, D.I., Seaman, M.S., et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc. Natl. Acad. Sci. USA 109 (2012), E3268–E3277.
126. Munro, J.B., Gorman, J., Ma, X., Zhou, Z., Arthos, J., Burton, D.R., Koff, W.C., Courter, J.R., Smith, A.B. 3rd, Kwong, P.D., et al. Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions. Science 346 (2014), 759–763.
127. Nabel, G.J., Designing tomorrow's vaccines. N. Engl. J. Med. 368 (2013), 551–560.
128. Ofek, G., Tang, M., Sambor, A., Katinger, H., Mascola, J.R., Wyatt, R., Kwong, P.D., Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 78 (2004), 10724–10737.
129. Ofek, G., Guenaga, F.J., Schief, W.R., Skinner, J., Baker, D., Wyatt, R., Kwong, P.D., Elicitation of structure-specific antibodies by epitope scaffolds. Proc. Natl. Acad. Sci. USA 107 (2010), 17880–17887.
130. Ofek, G., McKee, K., Yang, Y., Yang, Z.Y., Skinner, J., Guenaga, F.J., Wyatt, R., Zwick, M.B., Nabel, G.J., Mascola, J.R., Kwong, P.D., Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region. J. Virol. 84 (2010), 2955–2962.
131. Overbaugh, J., Morris, L., The antibody response against HIV-1. Cold Spring Harb. Perspect. Med., 2, 2012, a007039.
132. Pancera, M., Lebowitz, J., Schön, A., Zhu, P., Freire, E., Kwong, P.D., Roux, K.H., Sodroski, J., Wyatt, R., Soluble mimetics of human immunodeficiency virus type 1 viral spikes produced by replacement of the native trimerization domain with a heterologous trimerization motif: characterization and ligand binding analysis. J. Virol. 79 (2005), 9954–9969.
133. Pancera, M., Zhou, T., Druz, A., Georgiev, I.S., Soto, C., Gorman, J., Huang, J., Acharya, P., Chuang, G.Y., Ofek, G., et al. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature 514 (2014), 455–461.
134. Pantophlet, R., Wilson, I.A., Burton, D.R., Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design. J. Virol. 77 (2003), 5889–5901.
135. Pegu, A., Hessell, A.J., Mascola, J.R., Haigwood, N.L., Use of broadly neutralizing antibodies for HIV-1 prevention. Immunol. Rev. 275 (2017), 296–312.
136. Pejchal, R., Gach, J.S., Brunel, F.M., Cardoso, R.M., Stanfield, R.L., Dawson, P.E., Burton, D.R., Zwick, M.B., Wilson, I.A., A conformational switch in human immunodeficiency virus gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies. J. Virol. 83 (2009), 8451–8462.
137. Pejchal, R., Doores, K.J., Walker, L.M., Khayat, R., Huang, P.S., Wang, S.K., Stanfield, R.L., Julien, J.P., Ramos, A., Crispin, M., et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334 (2011), 1097–1103.
138. Posner, M.R., Cavacini, L.A., Emes, C.L., Power, J., Byrn, R., Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120. J. Acquir. Immune Defic. Syndr. 6 (1993), 7–14.
139. Richman, D.D., Wrin, T., Little, S.J., Petropoulos, C.J., Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. USA 100 (2003), 4144–4149.
140. Rudicell, R.S., Kwon, Y.D., Ko, S.Y., Pegu, A., Louder, M.K., Georgiev, I.S., Wu, X., Zhu, J., Boyington, J.C., Chen, X., et al., NISC Comparative Sequencing Program. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J. Virol. 88 (2014), 12669–12682.
141. Rujas, E., Caaveiro, J.M., Partida-Hanon, A., Gulzar, N., Morante, K., Apellániz, B., García-Porras, M., Bruix, M., Tsumoto, K., Scott, J.K., et al. Structural basis for broad neutralization of HIV-1 through the molecular recognition of 10E8 helical epitope at the membrane interface. Sci. Rep., 6, 2016, 38177.
142. Ruprecht, C.R., Krarup, A., Reynell, L., Mann, A.M., Brandenberg, O.F., Berlinger, L., Abela, I.A., Regoes, R.R., Günthard, H.F., Rusert, P., Trkola, A., MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. J. Exp. Med. 208 (2011), 439–454.
143. Rutten, L., Lai, Y.T., Blokland, S., Truan, D., Bisschop, I.J.M., Strokappe, N.M., Koornneef, A., van Manen, D., Chuang, G.Y., Farney, S.K., et al. A universal approach to optimize the folding and stability of prefusion-closed HIV-1 envelope trimers. Cell Rep. 23 (2018), 584–595.
144. Sanders, R.W., Moore, J.P., Native-like Env trimers as a platform for HIV-1 vaccine design. Immunol. Rev. 275 (2017), 161–182.
145. Sanders, R.W., Venturi, M., Schiffner, L., Kalyanaraman, R., Katinger, H., Lloyd, K.O., Kwong, P.D., Moore, J.P., The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J. Virol. 76 (2002), 7293–7305.
146. Sather, D.N., Armann, J., Ching, L.K., Mavrantoni, A., Sellhorn, G., Caldwell, Z., Yu, X., Wood, B., Self, S., Kalams, S., Stamatatos, L., Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83 (2009), 757–769.
147. Saunders, K.O., Nicely, N.I., Wiehe, K., Bonsignori, M., Meyerhoff, R.R., Parks, R., Walkowicz, W.E., Aussedat, B., Wu, N.R., Cai, F., et al. Vaccine elicitation of high mannose-dependent neutralizing antibodies against the V3-glycan broadly neutralizing epitope in nonhuman primates. Cell Rep. 18 (2017), 2175–2188.
148. Scanlan, C.N., Pantophlet, R., Wormald, M.R., Ollmann Saphire, E., Stanfield, R., Wilson, I.A., Katinger, H., Dwek, R.A., Rudd, P.M., Burton, D.R., The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1–>2 mannose residues on the outer face of gp120. J. Virol. 76 (2002), 7306–7321.
149. Scharf, L., Scheid, J.F., Lee, J.H., West, A.P. Jr., Chen, C., Gao, H., Gnanapragasam, P.N., Mares, R., Seaman, M.S., Ward, A.B., et al. Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. Cell Rep. 7 (2014), 785–795.
150. Scharf, L., Wang, H., Gao, H., Chen, S., McDowall, A.W., Bjorkman, P.J., Broadly neutralizing antibody 8ANC195 recognizes closed and open states of HIV-1 Env. Cell 162 (2015), 1379–1390.
151. Schatz, D.G., Spanopoulou, E., Biochemistry of V(D)J recombination. Curr. Top. Microbiol. Immunol. 290 (2005), 49–85.
152. Scheid, J.F., Mouquet, H., Ueberheide, B., Diskin, R., Klein, F., Oliveira, T.Y., Pietzsch, J., Fenyo, D., Abadir, A., Velinzon, K., et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333 (2011), 1633–1637.
153. Scheid, J.F., Horwitz, J.A., Bar-On, Y., Kreider, E.F., Lu, C.L., Lorenzi, J.C., Feldmann, A., Braunschweig, M., Nogueira, L., Oliveira, T., et al. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature 535 (2016), 556–560.
154. Seder, R.A., Chang, L.J., Enama, M.E., Zephir, K.L., Sarwar, U.N., Gordon, I.J., Holman, L.A., James, E.R., Billingsley, P.F., Gunasekera, A., et al., VRC 312 Study Team. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341 (2013), 1359–1365.
155. Sharma, S.K., de Val, N., Bale, S., Guenaga, J., Tran, K., Feng, Y., Dubrovskaya, V., Ward, A.B., Wyatt, R.T., Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design. Cell Rep. 11 (2015), 539–550.
156. Shingai, M., Nishimura, Y., Klein, F., Mouquet, H., Donau, O.K., Plishka, R., Buckler-White, A., Seaman, M., Piatak, M. Jr., Lifson, J.D., et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503 (2013), 277–280.
157. Shivatare, V.S., Shivatare, S.S., Lee, C.D., Liang, C.H., Liao, K.S., Cheng, Y.Y., Saidachary, G., Wu, C.Y., Lin, N.H., Kwong, P.D., et al. Unprecedented role of hybrid N-glycans as ligands for HIV-1 broadly neutralizing antibodies. J. Am. Chem. Soc. 140 (2018), 5202–5210.
158. Simek, M.D., Rida, W., Priddy, F.H., Pung, P., Carrow, E., Laufer, D.S., Lehrman, J.K., Boaz, M., Tarragona-Fiol, T., Miiro, G., et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83 (2009), 7337–7348.
159. Simonich, C.A., Williams, K.L., Verkerke, H.P., Williams, J.A., Nduati, R., Lee, K.K., Overbaugh, J., HIV-1 neutralizing antibodies with limited hypermutation from an infant. Cell 166 (2016), 77–87.
160. Sok, D., Laserson, U., Laserson, J., Liu, Y., Vigneault, F., Julien, J.P., Briney, B., Ramos, A., Saye, K.F., Le, K., et al. The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies. PLoS Pathog., 9, 2013, e1003754.
161. Sok, D., Doores, K.J., Briney, B., Le, K.M., Saye-Francisco, K.L., Ramos, A., Kulp, D.W., Julien, J.P., Menis, S., Wickramasinghe, L., et al. Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. Sci. Transl. Med., 6, 2014, 236ra63.
162. Sok, D., van Gils, M.J., Pauthner, M., Julien, J.P., Saye-Francisco, K.L., Hsueh, J., Briney, B., Lee, J.H., Le, K.M., Lee, P.S., et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc. Natl. Acad. Sci. USA 111 (2014), 17624–17629.
163. Sok, D., Briney, B., Jardine, J.G., Kulp, D.W., Menis, S., Pauthner, M., Wood, A., Lee, E.C., Le, K.M., Jones, M., et al. Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice. Science 353 (2016), 1557–1560.
164. Sok, D., Pauthner, M., Briney, B., Lee, J.H., Saye-Francisco, K.L., Hsueh, J., Ramos, A., Le, K.M., Jones, M., Jardine, J.G., et al. A prominent site of antibody vulnerability on HIV envelope incorporates a motif associated with CCR5 binding and its camouflaging glycans. Immunity 45 (2016), 31–45.
165. Stamatatos, L., Morris, L., Burton, D.R., Mascola, J.R., Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?. Nat. Med. 15 (2009), 866–870.
166. Stamatatos, L., Pancera, M., McGuire, A.T., Germline-targeting immunogens. Immunol. Rev. 275 (2017), 203–216.
167. Steichen, J.M., Kulp, D.W., Tokatlian, T., Escolano, A., Dosenovic, P., Stanfield, R.L., McCoy, L.E., Ozorowski, G., Hu, X., Kalyuzhniy, O., et al. HIV vaccine design to target germline precursors of glycan-dependent broadly neutralizing antibodies. Immunity 45 (2016), 483–496.
168. Stephenson, K.E., D'Couto, H.T., Barouch, D.H., New concepts in HIV-1 vaccine development. Curr. Opin. Immunol. 41 (2016), 39–46.
169. Stewart-Jones, G.B., Soto, C., Lemmin, T., Chuang, G.Y., Druz, A., Kong, R., Thomas, P.V., Wagh, K., Zhou, T., Behrens, A.J., et al. Trimeric HIV-1-Env structures define glycan shields from clades A, B, and G. Cell 165 (2016), 813–826.
170. Tan, J., Sack, B.K., Oyen, D., Zenklusen, I., Piccoli, L., Barbieri, S., Foglierini, M., Fregni, C.S., Marcandalli, J., Jongo, S., et al. A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein. Nat. Med. 24 (2018), 401–407.
171. Tian, M., Cheng, C., Chen, X., Duan, H., Cheng, H.L., Dao, M., Sheng, Z., Kimble, M., Wang, L., Lin, S., et al. Induction of HIV neutralizing antibody lineages in mice with diverse precursor repertoires. Cell 166 (2016), 1471–1484.e18.
172. Torrents de la Peña, A., Julien, J.P., de Taeye, S.W., Garces, F., Guttman, M., Ozorowski, G., Pritchard, L.K., Behrens, A.J., Go, E.P., Burger, J.A., et al. Improving the immunogenicity of native-like HIV-1 envelope trimers by hyperstabilization. Cell Rep. 20 (2017), 1805–1817.
173. UNAIDS (2016). Global AIDS Update 2016. http://www.unaids.org/en/resources/documents/2016/Global-AIDS-update-2016.
174. van Gils, M.J., van den Kerkhof, T.L., Ozorowski, G., Cottrell, C.A., Sok, D., Pauthner, M., Pallesen, J., de Val, N., Yasmeen, A., de Taeye, S.W., et al. An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. Nat. Microbiol., 2, 2016, 16199.
175. Verkoczy, L., Alt, F.W., Tian, M., Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies. Immunol. Rev. 275 (2017), 89–107.
176. Voss, J.E., Andrabi, R., McCoy, L.E., de Val, N., Fuller, R.P., Messmer, T., Su, C.Y., Sok, D., Khan, S.N., Garces, F., et al. Elicitation of neutralizing antibodies targeting the V2 apex of the HIV envelope trimer in a wild-type animal model. Cell Rep., 22, 2018, 1103.
177. Walker, L.M., Phogat, S.K., Chan-Hui, P.Y., Wagner, D., Phung, P., Goss, J.L., Wrin, T., Simek, M.D., Fling, S., Mitcham, J.L., et al., Protocol G Principal Investigators. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326 (2009), 285–289.
178. Walker, L.M., Simek, M.D., Priddy, F., Gach, J.S., Wagner, D., Zwick, M.B., Phogat, S.K., Poignard, P., Burton, D.R., A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog., 6, 2010, e1001028.
179. Walker, L.M., Huber, M., Doores, K.J., Falkowska, E., Pejchal, R., Julien, J.P., Wang, S.K., Ramos, A., Chan-Hui, P.Y., Moyle, M., et al., Protocol G Principal Investigators. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477 (2011), 466–470.
180. Wei, X., Decker, J.M., Wang, S., Hui, H., Kappes, J.C., Wu, X., Salazar-Gonzalez, J.F., Salazar, M.G., Kilby, J.M., Saag, M.S., et al. Antibody neutralization and escape by HIV-1. Nature 422 (2003), 307–312.
181. West, A.P. Jr., Diskin, R., Nussenzweig, M.C., Bjorkman, P.J., Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proc. Natl. Acad. Sci. USA 109 (2012), E2083–E2090.
182. Williams, L.D., Ofek, G., Schätzle, S., McDaniel, J.R., Lu, X., Nicely, N.I., Wu, L., Lougheed, C.S., Bradley, T., Louder, M.K., et al. Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. Sci. Immunol., 2, 2017 10.1126/sciimmunol.aal2200.
183. Williams, W.B., Zhang, J., Jiang, C., Nicely, N.I., Fera, D., Luo, K., Moody, M.A., Liao, H.X., Alam, S.M., Kepler, T.B., et al. Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. Nat. Commun., 8, 2017, 1732.
184. Wu, X., Yang, Z.Y., Li, Y., Hogerkorp, C.M., Schief, W.R., Seaman, M.S., Zhou, T., Schmidt, S.D., Wu, L., Xu, L., et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329 (2010), 856–861.
185. Wu, X., Zhou, T., Zhu, J., Zhang, B., Georgiev, I., Wang, C., Chen, X., Longo, N.S., Louder, M., McKee, K., et al., NISC Comparative Sequencing Program. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333 (2011), 1593–1602.
186. Wu, X., Zhang, Z., Schramm, C.A., Joyce, M.G., Kwon, Y.D., Zhou, T., Sheng, Z., Zhang, B., O'Dell, S., McKee, K., et al., NISC Comparative Sequencing Program. Maturation and diversity of the VRC01-antibody lineage over 15 years of chronic HIV-1 infection. Cell 161 (2015), 470–485.
187. Xiao, X., Chen, W., Feng, Y., Zhu, Z., Prabakaran, P., Wang, Y., Zhang, M.Y., Longo, N.S., Dimitrov, D.S., Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem. Biophys. Res. Commun. 390 (2009), 404–409.
188. Xu, K., Acharya, P., Kong, R., Cheng, C., Chuang, G.Y., Liu, K., Louder, M.K., O'Dell, S., Rawi, R., Sastry, M., et al. (2018). Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. bioRxiv. https://doi.org/10.1101/306282.
189. Yang, X., Lee, J., Mahony, E.M., Kwong, P.D., Wyatt, R., Sodroski, J., Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J. Virol. 76 (2002), 4634–4642.
190. Zhang, H., Fu, H., Luallen, R.J., Liu, B., Lee, F.H., Doms, R.W., Geng, Y., Antibodies elicited by yeast glycoproteins recognize HIV-1 virions and potently neutralize virions with high mannose N-glycans. Vaccine 33 (2015), 5140–5147.
191. Zhang, R., Verkoczy, L., Wiehe, K., Munir Alam, S., Nicely, N.I., Santra, S., Bradley, T., Pemble, C.W. 4th, Zhang, J., Gao, F., et al. Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages. Sci. Transl. Med., 8, 2016, 336ra62.
192. Zhao, L., Seth, A., Wibowo, N., Zhao, C.X., Mitter, N., Yu, C., Middelberg, A.P., Nanoparticle vaccines. Vaccine 32 (2014), 327–337.
193. Zhou, T., Xu, L., Dey, B., Hessell, A.J., Van Ryk, D., Xiang, S.H., Yang, X., Zhang, M.Y., Zwick, M.B., Arthos, J., et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445 (2007), 732–737.
194. Zhou, T., Georgiev, I., Wu, X., Yang, Z.Y., Dai, K., Finzi, A., Kwon, Y.D., Scheid, J.F., Shi, W., Xu, L., et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329 (2010), 811–817.
195. Zhou, T., Zhu, J., Wu, X., Moquin, S., Zhang, B., Acharya, P., Georgiev, I.S., Altae-Tran, H.R., Chuang, G.Y., Joyce, M.G., et al., NISC Comparative Sequencing Program. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity 39 (2013), 245–258.
196. Zhou, T., Zhu, J., Yang, Y., Gorman, J., Ofek, G., Srivatsan, S., Druz, A., Lees, C.R., Lu, G., Soto, C., et al. Transplanting supersites of HIV-1 vulnerability. PLoS ONE, 9, 2014, e99881.
197. Zhou, T., Lynch, R.M., Chen, L., Acharya, P., Wu, X., Doria-Rose, N.A., Joyce, M.G., Lingwood, D., Soto, C., Bailer, R.T., et al., NISC Comparative Sequencing Program. Structural repertoire of HIV-1-neutralizing antibodies targeting the CD4 supersite in 14 donors. Cell 161 (2015), 1280–1292.
198. Zhou, T., Doria-Rose, N.A., Cheng, C., Stewart-Jones, G.B.E., Chuang, G.Y., Chambers, M., Druz, A., Geng, H., McKee, K., Kwon, Y.D., et al. Quantification of the impact of the HIV-1-glycan shield on antibody elicitation. Cell Rep. 19 (2017), 719–732.
199. Zhou, T., Zheng, A., Baxa, U., Chuang, G.Y., Georgiev, I.S., Kong, R., O'Dell, S., Shahzad-Ul-Hussan, S., Shen, C.H., Tsybovsky, Y., et al., NISC Comparative Sequencing Program. A neutralizing antibody recognizing primarily N-linked glycan targets the silent face of the HIV envelope. Immunity 48 (2018), 500–513.e6.
200. Zhuang, J., Jetzt, A.E., Sun, G., Yu, H., Klarmann, G., Ron, Y., Preston, B.D., Dougherty, J.P., Human immunodeficiency virus type 1 recombination: rate, fidelity, and putative hot spots. J. Virol. 76 (2002), 11273–11282.